Fig. 1

Expression profile of HRD1 in different subtypes of breast cancer. a Expression of HRD1 at the protein and mRNA level in luminal (T47D, MCF-7, BT474) and basal-like (MDA-MB-231, BT549) breast cancer cell lines, examined by immunoblotting and RT-PCR with β-actin as a loading control. b RT-qPCR results of HRD1 expression in five kinds of breast cancer cells. β-actin was used as an internal control. c Scatter plots of HRD1 expression in 52 breast cancer cell lines from public microarray dataset (GSE41313). Luminal N = 29, TNBC N = 23. d Representative immunohistochemical staining of HRD1 protein expression in luminal breast cancer and TNBC tissues. Scale bar = 50 μm. e RT-qPCR results of HRD1 mRNA level in FFPE luminal (N = 5) and TNBC (N = 5) tissues. β-actin was used as an internal control. f Violin plots demonstrating the differential expression of HRD1 across the breast cancer subtypes, sampling from The Cancer Genome Atlas (TCGA-BRCA). LA (Luminal A) N = 486, LB (Luminal B) N = 79, HER2 N = 30, TNBC N = 123. One-way ANOVA was used for statistical analysis. g, h Box plots showing HRD1 expression in patients with luminal breast cancer or TNBC from public microarray datasets (GSE1456 and GSE5460). Luminal N = 62/76, TNBC N = 25/38. i Kaplan-Meier analysis showing the influence of HRD1 expression on relapse-free survival across the breast cancer subtypes from multiple public microarray datasets collected and organized by KM plotter. Data were represented as means ± S.D. of at least three independent experiments